# Biopta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biopta

- Industry: Pharmaceuticals
- Headquarters: Glasgow, UK
- Website: www.biopta.com
- Total disclosed funding: $1.2M
- Latest round: Series B (Oct 28, 2010)
- Investors on record: 3

## About

Biopta Ltd. is a biotechnology company focused on advancing preclinical and clinical research through innovative products and services, particularly in the fields of stem cell therapy and drug discovery.Biopta Ltd. specializes in providing advanced solutions for preclinical and clinical research. Founded in 2002, the company is headquartered in Glasgow, UK. In November 2015, Biopta was acquired by ReproCELL in a TRADE SALE for GBP 5.20 million, marking a pivotal shift in its operational strategy. The founder's history is not publicly detailed, but the company has successfully completed five deals to date.Biopta Ltd. offers a comprehensive suite of products aimed at enhancing preclinical and clinical research. Their offerings include stem cell reagents, 3D cell culture systems, and specialized services like the StemEdit Clinical Gene Editing Service, utilizing CRISPR technology for precise genetic modifications. These products cater to researchers in pharmaceuticals, biotechnology, and academic institutions, facilitating advancements in immuno-oncology, regenerative medicine, and personalized therapies.Biopta Ltd. operates on a direct-to-business model, supplying products and services to academia and industry stakeholders involved in biomedical research. Revenue is generated through sales of individual products, including the StemRNA™ 3rd Gen Reprogramming Kit and the Alvetex® 3D Cell Culture Systems, as well as through service contracts for specialized offerings like GMP-compliant master cell bank manufacturing. This model fosters ongoing relationships with clients, who frequently engage in purchasing agreements essential for their research and development projects.Biopta Ltd. aims to leverage its recent acquisition by ReproCELL to expand its product offerings and market reach. Following the acquisition in November 2015, the company plans to develop new products targeting advancements in stem cell therapies and gene editing technologies. Additionally, there are intentions to penetrate new geographical markets, particularly in Europe and Asia, by 2025. The recent funding will support these initiatives, enhancing R&D capabilities and facilitating market entry strategies.

## Funding rounds

- Series B, Oct 28, 2010, $0.4M — Truetide, Tweed Renaissance Investors Capital (TRI Cap), Scottish Enterprise
- Series A, Nov 5, 2004, $0.8M — Truetide

## Investors

- Truetide (https://capitalatlas.ai/funds/truetide) — Series A, Series B
- Tweed Renaissance Investors Capital (TRI Cap) — Series B
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Series B